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Aft er adjusting for age, sex, prevalent car-
diovascular disease, hypertension, diabe-
tes, smoking, cholesterol, and albuminuria, 
the Chronic Kidney Disease Prognosis 
Consortium collaborators also found the 
turning point to be 75  ml / min per 1.73  m 2 . 
Th e traditional Cox regression analysis 
with post-estimation  C statistics for com-
parison of diff erent models is known to 
have a rather low ability to diff erentiate 
between models even if these are of sub-
stantially diff erent clinical importance. 
Other techniques have been suggested, 
and a few studies have used these new 
techniques on the current topic. Soveri  et 
al. analyzed a rather small but well-char-
acterized cohort of Swedish men ( n  =  2176) 
using the integrated discrimination 
improvement method. 10 Th ey found that 
the optimal cutoff  for predicting cardio-
vascular death was 92  ml / min per 1.73  m 2 , 
which is in accordance with the results of 
the study by Foley  et al. 6 
 Th e study by Foley  et al. , 6 as well as pre-
vious studies, clearly shows that kidney 
function and albuminuria are among the 
most important cardiovascular risk factors. 
Th is information has not yet been imple-
mented in clinical practice in an appropri-
ate way. Very few clinical guidelines on 
hypertension and cardiovascular disease 
mention eGFR and albuminuria as impor-
tant risk factors. 5 Furthermore, none of the 
commonly used risk equations has included 
these risk factors. An intensifi ed collabora-
tion between nephrologists and cardiolo-
gists is therefore highly recommended, in 
research, guideline development, and clin-
ical practice. As the very interesting article 
by Foley  et al. 6 indicates, the optimal cutoff  
values for prediction of mortality risk 
might not yet have been decided on. How-
ever, physicians should already now start 
to pay attention to kidney-related variables 
for risk stratifi cation. Chronic kidney dis-
ease is defi nitely a major cardiovascular 
risk factor that deserves full attention. 
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 Ischemia / reperfusion injury (IRI) is a common cause of acute kidney 
injury (AKI) that is associated with a patient mortality of up to 50 % . 
Currently there are not effective pharmacologic therapies for AKI. This 
Commentary highlights recent evidence indicating that 20-HETE plays 
an important role in IRI and that drugs that target this pathway have 
potential as therapeutic agents for AKI.  
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Ischemia / reperfusion injury (IRI) is a 
common cause of acute kidney injury 
(AKI) in a variety of clinical settings 
ranging from critical illness to renal 
transplantation. 1 AKI increases patient 
morbidity and is associated with patient 
mortality of up to 50 % . 1 Currently, there 
are no effective pharmacologic therapies 
for AKI in humans. Thus, there is a pro-
found need for new treatments for AKI. 
 Recent studies have reported that 
HET0016, a selective inhibitor of 20-
hydroxyeicosatetraenoic acid (20-HETE) 
synthesis, reduces infarct size in the brain 
and heart following IRI. 2 – 4 Interestingly, 
the benefi cial eff ect following IRI to the 
brain is independent of changes in cere-
bral blood fl ow, suggesting that the inhib-
itors of the synthesis of 20-HETE may 
have direct neuroprotective actions. 4 
Until recently, the role of CYP metabo-
lites of arachidonic acid in AKI had not 
been well characterized. The study 
by Hoff   et al. 5 (this issue) indicates that 
20-HETE may play a central role in renal 
IRI, and that agents that target the 
20-HETE pathway have the potential to 
minimize kidney injury. 
 Th e study by Hoff   et al. 5 is important 
because it provides the fi rst direct evi-
dence that renal 20-HETE levels increase 
during ischemia. Th e authors found that 
the release of 20-HETE increased four-
fold following ischemia in an isolated 
perfused kidney, and that this was attenu-
ated by 50 % by inclusion of 100  n m 
HET0016 in the perfusion solution. Simi-
larly, tissue levels of free 20-HETE 
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increased tenfold following 45  min of 
warm ischemia in the single remaining 
kidney of uninephrectomized rats. Pre-
treatment of the rats with HET0016 
attenuated the increase in 20-HETE levels 
and reduced the degree of IRI by about 
50 % . Similar eff ects were seen following 
an intrarenal artery injection of 6,15-20-
HEDE, which antagonizes the vasocon-
strictor actions of 20-HETE. 6 In contrast, 
administration of the 20-HETE agonist 
5,14-20-HEDE had no effect on the 
degree of IRI. 
 However, the study of Hoff   et al. 5 raises 
many questions. Th e fi rst concerns the 
dose of the compounds and whether they 
are suffi  cient to inhibit the synthesis and 
actions of 20-HETE. Hoff   et al. 5 pretreated 
rats with a 50-  g bolus injection of 
HET0016 into the renal artery. Assuming 
that renal blood fl ow was 10  ml / min, the 
fi rst-pass concentration should have been 
20   m . However, HET0016 is highly bound 
to plasma proteins (>95 % ), so the free 
concentration that can cross the peritubu-
lar capillaries and reach the renal tubules 
would be closer to 1   m . This concen-
tration should be sufficient to inhibit 
20-HETE production, as the half-maximal 
inhibitory concentration in rat renal 
microsomes is less than 32  n m . 7 Moreover, 
Hoff   et al. 5 show that HET0016 attenuated 
the increase in 20-HETE levels associated 
with ischemia. However, after the first 
pass through the kidney, the drug should 
redistribute, and the concentration 
remaining in the kidney may have 
been insufficient to inhibit 20-HETE 
synthesis, especially during the reper-
fusion period. 
 A better understanding of the pharma-
cokinetics is also needed to interpret the 
eff ects of the 20-HETE antagonist 6,15-
20-HEDE on IRI. Hoff   et al. 5 administered 
a 20-  g bolus dose into the renal artery, 
which should produce a fi rst-pass concen-
tration of 6   m . Like 20-HETE, however, 
this compound is extensively bound to 
plasma proteins, so the free concentration 
was probably less than 1   m . Th is com-
pound should also rapidly redistribute 
and is subject to metabolism by   -oxida-
tion, lipoxygenase, and epoxygenase 
enzymes. Th us, the free concentration in 
the kidney during the ischemic and reper-
fusion periods should have been lower 
than 1   m . Regardless of this issue, Hoff  
 et al. 5 clearly demonstrated that the com-
pound had a beneficial effect, but it 
remains to be determined whether the tis-
sue levels of 6,15-20-HEDE were high 
enough to inhibit the tubular or vascular 
effects of 20-HETE or whether it acts 
through some other mechanism. 
 Th e fi nal issue concerns the mecha-
nism of action of the 20-HETE in IRI. 
Hoff   et al. 5 report that pretreatment of 
the rats with the 20-HETE antagonist 
improved reperfusion of the renal 
medulla and increased tissue PO 2 levels. 
Th ey suggest that the eff ects of both 6,15-
20-HEDE and HET0016 might be sec-
ondary to blockade of the vasoconstrictor 
actions of 20-HETE. However, the con-
centration of 20-HETE in the kidney 
only rose from 6 to 60  n m during the 
ischemic period. Th e authors indicate 
that the threshold concentration for the 
renal vasoconstrictor actions of 20-HETE 
is 1  n m . 8 However, this is true only in iso-
lated vessels in the absence of blood or 
protein, which avidly binds 20-HETE 
and other lipids. Much higher concentra-
tions (1 – 10   m ) are typically needed to 
elicit vasoconstriction  in vivo . 9 More-
over, although 20-HETE is a potent vaso-
constrictor, it is not very effi  cacious, and 
maximal concentrations of 20-HETE 
reduce the diameter of isolated vessels by 
only 14 % . 8 If 20-HETE elevates renal vas-
cular tone following IRI, then blockade of 
the synthesis or actions of 20-HETE with 
HET0016 or 6,15-20-HEDE should have 
produced a profound hyperemia. Instead, 
6,15-20-HEDE had no eff ect on whole-
kidney or cortical blood fl ow and pro-
duced only a transient improvement in 
medullary blood fl ow. Th us, additional 
studies are needed to determine whether 
elevated levels of 20-HETE contribute to 
IRI by enhancing vasoconstriction in the 
medullary circulation. 
 For these reasons, it seems more likely 
that the benefi cial eff ect of blocking the 
synthesis and action of 20-HETE might 
be related to the elevation in PO 2 in the 
postischemic period. The mechanism 
responsible for this eff ect is unclear, as the 
20-HETE inhibitors did not increase renal 
perfusion. Furthermore, 20-HETE inhib-
its sodium transport in the proximal 
tubule and thick ascending loop of Henle, 9 
so blockade of 20-HETE activity would be 
expected to enhance rather than inhibit 
tubular transport and oxygen utilization. 
Hoff   et al. 5 suggest that perhaps the eleva-
tion in PO 2 might be related to an increase 
in nitric oxide availability secondary to a 
fall in reactive oxygen species, since 
20-HETE stimulates production of reac-
tive oxygen species both by activating 
NADPH oxidase and through nitric oxide 
synthase uncoupling. 10 Nitric oxide is 
known to diminish oxygen utilization 
through several mechanisms. 
 Although the results of the study by 
Hoff   et al. 5 are consistent with previous 
fi ndings that inhibitors of 20-HETE syn-
thesis reduce IRI in the heart and brain, it 
should be noted that these fi ndings are in 
direct opposition to an earlier study by 
Regner  et al. 11 In that study, HET0016 
enhanced rather than opposed renal IRI, 
and systemic administration of the 
20-HETE analogs 5,14-20-HEDE and 
5,14,20-HEDGE reduced renal IRI and 
produced a sustained increase in medul-
lary blood flow following ischemia in 
rats. 11 Furthermore, 5,14-20-HEDGE was 
found to inhibit sodium transport and 
produced diuresis and natriuresis in nor-
mal rats. Th e authors concluded that the 
protective eff ect of the 20-HETE analogs 
in renal IRI was due to prevention of 
post ischemic medullary hypoxia through 
a simultaneous increase in renal medul-
lary blood fl ow and attenuation of tubular 
transport and oxygen demand. Indeed, 
20-HETE has been shown to increase 
renal medullary blood fl ow in rats 12 and 
to inhibit renal tubular Na   +   -K   +   -ATPase 
activity and sodium transport in the proxi-
mal tubule and medullary thick ascending 
loop of Henle. 9 
 Although there is no obvious way to 
reconcile the divergent conclusions of 
these two studies, there are some impor-
tant diff erences in the experimental design 
that should be noted. Regner  et al. 11 
administered HET0016 subcutaneously at 
a dose of 10  mg / kg, which has been shown 
to produce blood levels of about 4   M and 
selectively inhibits the renal synthesis of 
20-HETE for several hours. 13 Th is con-
trasts with the study of Hoff  et al. , 5 
in which the drug was delivered directly 
into the renal artery and the kidney was 
probably exposed to a higher fi rst-pass 
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concentration but a lower concentration 
during the ischemic and postischemic 
periods. Similarly, the systemic adminis-
tration of the 20-HETE analogs 5,14-20-
HEDE and 5,14-20-HEDGE by Regner 
 et al. 11 produced sustained blood levels of 
about 1   m throughout the experiment, 
whereas the intrarenal injection of 5,14-
20-HEDE by Hoff   et al. 5 probably pro-
duced a higher first-pass blood level 
but much lower levels after the drug 
redistributed. Finally, the IRI models used 
in these two studies were very diff erent. 
Regner  et al. 11 used Sprague Dawley rats 
and warm bilateral ischemia for 30  min, 
whereas Hoff   et al. 5 studied Lewis rats that 
were uninephrectomized and then sub-
jected to warm ischemia of the remaining 
kidney for 45  min. Although it remains to 
be determined why uninephrectomy alters 
the response to 20-HETE inhibitors in 
IRI, the results presented in  Figure 1 indi-
cate that this is a potential answer to the 
diff erence in the results between the two 
studies. In our previous study, administra-
tion of HET0016 (10  mg / kg, subcuta-
neously) enhanced renal injury and 
increased plasma creatinine levels 24  h 
after 30  min of bilateral ischemia in 
Sprague Dawley rats. 11 On the other hand, 
we recently confi rmed the fi ndings of Hoff  
 et al. 5 and show in  Figure 1 that HET0016 
(10  mg / kg, subcutaneously) does reduce 
IRI when given to uninephrectomized rats 
subjected to 45  min of renal ischemia. 
 Following ischemia, the intracellular 
Ca 2  +   concentration increases and activates 
phospholipase A 2 to promote the release 
of arachidonic acid from membrane phos-
pholipid pools. Arachidonic acid can be 
metabolized into prostaglandins, leukot-
rienes, and 5-, 12-, and 15-HETE by cyc-
looxygenases and lipo xygenases, and into 
20-HETE and epoxyeicosatrienoic acids 
via cytochrome P450 pathways. 9 Of these 
metabolites, 20-HETE has numerous 
eff ects on renal tubular and vascular func-
tion and activates a number of signaling 
pathways that could potentiate or oppose 
renal IRI. In this regard, 20-HETE may 
exacerbate postischemic reductions in 
renal blood fl ow, leading to secondary 
ischemic injury, as it is a potent vasocon-
strictor of preglomerular vessels. 8 Pro-
longed exposure to high concentrations 
of 20-HETE may also enhance renal IRI 
by increasing the generation of reactive 
oxygen species. 14 On the other hand, 
20-HETE may attenuate renal IRI by 
mitigating medullary hypoxia, since it 
increases medullary blood flow and 
inhibits tubular sodium transport. 9,12 
Finally, 20-HETE modulates a number of 
intracellular signal transduction pathways 
critical to cell fate in renal IRI. Indeed, we 
recently demonstrated that 20-HETE and 
5,14-20-HEDE activates the Raf – MEK –
 ERK and phosphatidylinositol-3  -kinase –
 AKT pathways in renal tubular epithelial 
cells. 15 Th is is intriguing because activa-
tion of the ERK1 / 2 pathway enhances 
renal epithelial-cell survival in models of 
renal IRI. 16,17 In conclusion, the results of 
the studies by Hoff   et al. , 5 Regner  et al. , 11 
and Nilakantan  et al. 14 indicate that the 
20-HETE pathway is activated during 
renal ischemia and that it has the poten-
tial to augment or mitigate IRI through a 
variety of mechanisms. The results of 
these studies further suggest that drugs 
that target the 20-HETE pathway may 
have a therapeutic potential to treat AKI. 
In order to translate these therapies to 
clinical use, more work is needed to 
determine the optimal dose, route of 
administration, and timing of adminis-
tration of either 20-HETE inhibitors or 
20-HETE agonists. 
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 Figure 1  |  Contrasting effects of HET0016, 24  h after 30  min of bilateral renal IRI, or after 
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